Litcius/Paper detail

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Aleix Prat, Valentina Guarneri, Laia Paré, Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci, Núria Chic, Blanca González‐Farré, Antonio Frassoldati, Esther Sanfeliu, Juan Miguel Cejalvo, Montserrat Muñoz-Mateu, Giancarlo Bisagni, Fara Brasó‐Maristany, Loredana Urso, María Vidal, Alba A. Brandes, Bárbara Adamo, Antonino Musolino, Federica Miglietta, Benedetta Conte, Mafalda Oliveira, Cristina Saura, Sònia Pernas, Jesús Alarcón, Antonio Llombart‐Cussac, Javier Cortés, Luís Manso, Rafael López‐López, Eva Ciruelos, Francesco Schettini, Patricia Villagrasa, Lisa A. Carey, Charles M. Perou, Federico Piacentini, Roberto D’Amico, Enrico Tagliafico, Joel S. Parker, PierFranco Conte

2020The Lancet Oncology75 citationsDOIOpen Access PDF

Topics & Concepts

MedicineBreast cancerInternal medicineOncologyLymphovascular invasionTaxaneTrastuzumabAnthracyclineRetrospective cohort studyCancerStage (stratigraphy)Clinical endpointClinical trialMetastasisPaleontologyBiologyBreast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchAdvanced Breast Cancer Therapies
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation | Litcius